FDA Pipeline Preview, June 2011 (BioMimetic Therapeutics, Pfizer, D-Pharm, Bayer HealthCare Pharmaceuticals, Mithridion, Cytonet)

Recent FDA action (through May 2011) related to Augment Bone Graft, crizotinib, DP-b99 development program, regorafenib, MCD-386CR, liver cell infusion of donated human liver cells

Recommended for approval

Priority review

Fast-track designations

© 2023 MJH Life Sciences

All rights reserved.